Last Updated: November 8, 2026

Details for Patent: 12,673,035

« Back to Dashboard


Which drugs does patent 12,673,035 protect, and when does it expire?

Patent 12,673,035 protects IQIRVO and is included in one NDA.

This patent has eleven patent family members in eleven countries.

Summary for Patent: 12,673,035
Title:Solid dosage forms of elafibranor
Abstract:The present invention relates to formulations of elafibranor or a pharmaceutically acceptable salt or ester thereof; and uses thereof. In particular, the present invention relates to an oral solid dosage form comprising at least elafibranor or a pharmaceutically acceptable salt or ester thereof; a filler, a disintegrating agent and a binder.
Inventor(s):Alice Roudot, Marie-Jeanne JOISSAINS
Assignee: Genfit SA
Application Number:US19/302,463
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 12,673,035

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen IQIRVO elafibranor TABLET;ORAL 218860-001 Jun 10, 2024 RX Yes Yes 12,673,035 ⤷  Start Trial Y TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,673,035

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2024231686 ⤷  Start Trial
China 120826225 ⤷  Start Trial
Colombia 2025012602 ⤷  Start Trial
European Patent Office 4676456 ⤷  Start Trial
Israel 322676 ⤷  Start Trial
Jordan P20250224 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.